Literature DB >> 17345785

Current usage of diuretics among hypertensive patients in Japan: the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study.

Kayo Murai1, Taku Obara, Takayoshi Ohkubo, Hirohito Metoki, Takuya Oikawa, Ryusuke Inoue, Rie Komai, Tsuyoshi Horikawa, Kei Asayama, Masahiro Kikuya, Kazuhito Totsune, Junichiro Hashimoto, Yutaka Imai.   

Abstract

In the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study, we examined the current situation with respect to the prescription of diuretics, including the prevalence of diuretic treatment and the dosages used for patients with essential hypertension in primary care settings. Of the 3,400 hypertensive patients included in the study, 315 (9.3%) patients (mean age: 66.9+/-10.4 years; males: 43.5%) were prescribed diuretics. Compared with patients who were not using diuretics, those who were using diuretics were more obese and had more complications. The most commonly prescribed diuretic among the 331 prescriptions in the 315 diuretic users was trichlormethiazide (44%), followed by indapamide (15%) and spironolactone (14%). Among patients being treated with diuretics, monotherapy was used in only 5% of patients; in the majority of patients combination therapy including diuretics (95%) was used. Relatively low dosages of diuretics were generally used. There was a difference between the actual dosages prescribed and those recommended by the Japanese Society of Hypertension (JSH) guidelines or the product information approved in Japan. Compared with previous estimates of the prevalence of diuretic use in hypertensives in Japan (4.0-5.4%), the rate in the J-HOME study (9.3%) was higher. This may be attributable at least in part to the results of the many published, large-scale intervention trials confirming the clinical significance of diuretics. Although a relatively high dosage is recommended in the diuretic product information and in the JSH guidelines, dosages of diuretics should be reconsidered in Japan.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17345785     DOI: 10.1291/hypres.29.857

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  6 in total

1.  Antihypertensive efficacy of the losartan/hydrochlorothiazide combination and its effect on plasma B-type natriuretic peptide in hypertensive patients uncontrolled by angiotensin II type 1 receptor antagonist-based therapy: a multicentre prospective observational study.

Authors:  Hiroshi Meno; Tetsuji Inou; Michiko Tanaka; Yoshihiro Tsuchiya; Yuhei Shiga; Kenji Kobayashi; Yuichiro Nakamura; Takeaki Ota; Ichiro Kubara
Journal:  Clin Drug Investig       Date:  2012-03-01       Impact factor: 2.859

2.  Three-year safety and effectiveness of fixed-dose losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension under clinical setting (PALM-1 Extension Study).

Authors:  Toshihiro Kita; Naoto Yokota; Yoshinari Ichiki; Takao Ayabe; Takuma Etoh; Noboru Tamaki; Johji Kato; Tanenao Eto; Kazuo Kitamura
Journal:  Clin Exp Hypertens       Date:  2012-04-25       Impact factor: 1.749

3.  Adverse effect profile of trichlormethiazide: a retrospective observational study.

Authors:  Yasuo Takahashi; Yayoi Nishida; Tomohiro Nakayama; Satoshi Asai
Journal:  Cardiovasc Diabetol       Date:  2011-05-23       Impact factor: 9.951

4.  Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial.

Authors:  Toshio Ogihara; Takao Saruta; Hiromi Rakugi; Ikuo Saito; Kazuaki Shimamoto; Hiroaki Matsuoka; Kazuyuki Shimada; Sadayoshi Ito; Masatsugu Horiuchi; Tsutomu Imaizumi; Shuichi Takishita; Jitsuo Higaki; Shigehiro Katayama; Genjiroh Kimura; Satoshi Umemura; Nobuyuki Ura; Koichi Hayashi; Masato Odawara; Norio Tanahashi; Toshihiko Ishimitsu; Naoki Kashihara; Satoshi Morita; Satoshi Teramukai
Journal:  J Hypertens       Date:  2014-10       Impact factor: 4.844

Review 5.  Home and Office Blood Pressure Control among Treated Hypertensive Patients in Japan: Findings from the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) Study.

Authors:  Taku Obara; Takayoshi Ohkubo; Michihiro Satoh; Nariyasu Mano; Yutaka Imai
Journal:  Pharmaceuticals (Basel)       Date:  2010-02-04

6.  The use of olmesartan medoxomil as monotherapy or in combination with other antihypertensive agents in elderly hypertensive patients in Japan.

Authors:  Ikuo Saito; Toshio Kushiro; Koji Hirata; Yuki Sato; Fumiaki Kobayashi; Kei Sagawa; Katsutoshi Hiramatsu; Masahiro Komiya
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-04       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.